drugset / Trial / NCT05434091
A First-In-Human Study of the Study Medicine, Called PF-07291177, in Healthy Adult Participants
RandomizedCrossoverDouble-blindBasic science
Summary
The purpose of the study is to learn about the safety, tolerability (the extent to which side effects can be tolerated), and plasma pharmacokinetics (PK) (PK helps us understand how the drug is changed and eliminated from body after you take it) of PF-07291177 after administration of escalating, single, doses by mouth.
Timeline
- Start
- 2022-08-15
- Primary completion
- 2023-03-29
- Completion
- 2023-03-29
Outcome
Outcome not reported
Stopped (Business): “Study stopped due to change in strategy.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-07291177 | Unknown | — | Oral |
Indications
No indication recorded.